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an-Malte Sinning, MD, Alexander Ghanem, MD, Hannah Steinhäuser, MD,
iktoria Adenauer, MD, Christoph Hammerstingl, MD, Georg Nickenig, MD,
ikos Werner, MD
onn, Germany
bjectives The aim of this study was to determine the inﬂuence of baseline renal function and
eriprocedural acute kidney injury (AKI) on prognosis after transcatheter aortic valve implantation
TAVI).
ackground Evidence is growing that renal function is a major predictor of mortality in patients
fter TAVI.
ethods TAVI was performed with the 18-F CoreValve prosthesis via transfemoral access. All-cause
ortality was determined 30 days and 1 year after TAVI in 77 patients with a mean Society of Tho-
acic Surgeons mortality score of 9.3  6.1% and a mean logistic European System for Cardiac Oper-
tive Risk Evaluation of 31.2  17.6%.
esults Overall procedural success rate was 98% with 1 periprocedural death. The 30-day mortality
as 10%, and 1-year mortality was 26%. The mortality risk increased stepwise across quartiles of
aseline serum creatinine. An AKI occurred in 20 of 77 patients: 12 patients (60%) with AKI died dur-
ng follow-up. The incidence of AKI was related to peripheral arterial disease (65% vs. 39%; p 
.04), the occurrence of a systemic inﬂammatory response syndrome (60% vs. 21%, p  0.002), and
ost-procedural peri-prosthetic regurgitation 2 (35% vs. 9%, p  0.02). Impaired renal function
t baseline reﬂected by serum creatinine 1.58 mg/dl (hazard ratio: 3.9, 95% conﬁdence interval: 1.6
o 9.5; p  0.002) and the occurrence of AKI (hazard ratio: 5.9, 95% conﬁdence interval: 2.4 to 14.5,
 0.001) that was not related to the amount of contrast dye were strong predictors of 1-year
ortality after TAVI.
onclusions Impaired renal function at baseline and the occurrence of periprocedural AKI, indepen-
ent whether renal function returns to baseline or not, are strong predictors of 30-day and 1-year
ortality after TAVI. (J Am Coll Cardiol Intv 2010;3:1141–9) © 2010 by the American College of
ardiology Foundation
rom the Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Rheinische Friedrich-Wilhelms-Universität, Bonn,
ermany. All authors have reported that they have no relationships to disclose.anuscript received July 6, 2010; revised manuscript received August 24, 2010, accepted September 3, 2010.
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1142ith the growing older population, severe aortic stenosis in
lderly patients who have multiple and complex comorbidi-
ies and are unsuitable for surgical valve replacement is
ecoming more and more prevalent. According to the Euro
eart Survey, more than 30% of all patients with valvular
eart disease do not undergo surgical valve replacement,
ainly due to advanced age and the prevalence of multiple
omorbidities (1). However, conservatively treated patients
ith severe aortic stenosis have a grave prognosis, which is
ven worse in the presence of advanced age, left ventricular
ysfunction, heart failure, and renal failure (2). Since 2002,
ranscatheter aortic valve implantation (TAVI) has been
stablished as an emerging therapeutic option for these
igh-risk patients (3–10).
Acute kidney injury (AKI) oc-
curs in up to 30% of all patients
undergoing cardiac surgery and
is associated with substantial
morbidity and mortality, inde-
pendent of all other factors (11).
An AKI after conventional car-
diac surgery or percutaneous
coronary intervention is associ-
ated with prolonged hospital
stay and increased short- and
long-term mortality (12–16).
Evidence is growing that renal
function might be an indepen-
dent predictor of mortality after
TAVI (17,18). In a recent study,
the occurrence of AKI was asso-
ciated with increased in-hospital
mortality after TAVI, although
the incidence was lower than in
comparable patients after surgi-
cal aortic valve replacement (19).
The purpose of our study was
to determine the influence of
baseline renal function on prog-
nosis after TAVI and to assess
he prognostic implication of post-procedural AKI on
hort- and mid-term outcome.
ethods
atients. Patients with severe, symptomatic aortic stenosis
nd no reasonable surgical option due to excessive periop-
rative risk underwent planned TAVI at our institution.
ithin this observational, prospective study, 77 consecutive
atients were included into the study after written informed
onsent was obtained. Five patients receiving chronic dial-
sis (logistic European System for Cardiac Operative Risk
valuation [EuroSCORE] 23.0  12.4%, Society of Tho-
bbreviations
nd Acronyms
KI  acute kidney injury
ABG  coronary artery
ypass grafting
I  confidence interval
OPD  chronic obstructive
ulmonary disease
RP  C-reactive protein
GFR  estimated
lomerular filtration rate
uroSCORE  European
ystem for Cardiac Operative
isk Evaluation
R  hazard ratio
T-proBNP  N-terminal
rohormone brain natriuretic
eptide
IRS  systemic
nflammatory response
yndrome
TS  Society of Thoracic
urgeons
AVI  transcatheter aortic
alve implantationacic Surgeons [STS] mortality score 7.9  3.0%, 30-day tortality: 0%, in-hospital mortality: 1 of 5, 1-year mortal-
ty: 1 of 5) were excluded from this analysis, because AKI
ould not be an issue in these patients. In preparation for
AVI, coronary anatomy and hemodynamic status were
ssessed by coronary angiography and left and right heart
atheterization. Valvular anatomy and annulus dimension
ere evaluated with transthoracic and transesophageal
chocardiography (including 3-dimensional reconstruction),
ontrast angiography of the aortic root, and multislice
omputer tomography of the thoracic aorta. The vascular
ccess site was assessed by color-coded Doppler sonography
nd multislice computer tomography or contrast angiogra-
hy of the abdominal aorta and the aortoiliofemoral system.
cceptance for TAVI required a consensus by a team of
ardiac surgeons and cardiologists.
Median follow-up time was 283 days (interquartile range:
9 to 439 days). The clinical end point of the study was
ll-cause mortality 30 days and 1 year after TAVI. Infor-
ation about the cause of death was obtained from the
reating hospital or general practitioner charts. The study
as approved by the local ethics committee of the University
f Bonn.
Systemic inflammatory response syndrome (SIRS) was
efined according to existing guidelines as fulfilling at least
of the following criteria (20): temperature 36.0°C or
38.0°C, heart rate 90 beats/min, respiratory rate 20/
in or hyperventilation (PaCO2 33 mm Hg), leukocyte
ount 12 or 4 (109/l).
alve implantation. Procedures were performed with bi-
lane fluoroscopy under local anesthesia in combination
ith a systemic sedative/analgesic treatment (fentanyl, mi-
azolam). Patients were pre-medicated with 500-mg aspi-
in, 300 mg clopidogrel, and 2 g ceftriaxone. Patients with
re-procedural chronic kidney disease received intravenous
ydration and N-acetylcysteine before and after TAVI and
ere prophylactically treated with intravenous bicarbonate
o prevent contrast-induced nephropathy. Visipaque 320
GE Healthcare, Munich, Germany) was used as contrast
edium in patients with chronic kidney disease. Vascular
ccess was obtained through a percutaneous 18-F sheath
laced in the common femoral artery (1 patient received
urgical preparation of the common femoral artery and
onsecutive surgical closure due to femoropopliteal bypass).
fter pre-dilation of the native aortic valve with a 22-mm or
5-mm NuCLEUS Percutaneous Transluminal Valvulo-
lasty catheter (NuMED, Inc., Baylis Medical, Montreal,
uebec, Canada) during right ventricular burst pacing, the
elf-expandable 18-F CoreValve prosthesis (CoreValve Re-
alving Technology, Medtronic, Minneapolis, Minnesota)
as advanced retrogradely and deployed within the aortic
nnulus (26 mm or 29 mm prosthesis according to the
ecommendations of the manufacturer). The femoral punc-
ure site was closed percutaneously with the use of the
P
I
L
o
p
S
m
c
D
a
s
i
o
h
w
b
(
s
(
C
t
G
S
m
q
v
u
t
c
fi
s
1
K
w
T
R
9
w
I
R
B
p
f
B
w
m
S
c
p
(
s
(
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 3 , N O . 1 1 , 2 0 1 0 Sinning et al.
N O V E M B E R 2 0 1 0 : 1 1 4 1 – 9 Renal Function Predicts Mortality After TAVI
1143rostar XL suture device (Abbott Vascular, Abbott Park,
llinois).
aboratory methods. Serum creatinine levels were measured
n the day before TAVI and on days 1, 2, 3, and 7 in all
atients (ECREA Flex reagent cartridge, Dimension Vista,
iemens Healthcare Diagnostics GmbH, Munich, Ger-
any). Estimated glomerular filtration rate (eGFR) was
alculated by the simplified Modification of Diet in Renal
isease formula (21). Chronic renal failure was defined as
n eGFR 60 ml/min; AKI as an absolute increase in
erum creatinine of0.3 mg/dl (26.4 mol/l); percentage
ncrease in serum creatinine of 50%; or reduction in urine
utput, defined as 0.5 ml/kg/h for more than 6 h, in 48
after TAVI according to the Acute Kidney Injury Net-
ork classification (15). The N-terminal pro-hormone
rain natriuretic peptide (NT-proBNP), C-reactive protein
CRP), troponin I, and lactate levels were routinely mea-
ured on the day before and the second day after TAVI
PBNP Flex reagent cartridge, CRP Flex reagent cartridge,
TNI Flex reagent cartridge, and LA Flex reagent car-
ridge; Dimension Vista, Siemens Healthcare Diagnostics
mbH, Munich, Germany).
tatistical analysis. Continuous variables are presented as
ean  SD if normally distributed and as median (inter-
uartile range) if not normally distributed. Categorical
ariables are given as frequencies and percentages. Contin-
ous variables were tested for differences with the Student
Table 1. Baseline Characteristics of Study Population According to Outcom
All Patients (n  77) Survivors (n  57)
Age (yrs) 80.8  6.7 81.0  6.8
Female 40 (52) 31 (54)
Logistic EuroSCORE (%) 31.2  17.6 27.6  16.7
STS score: mortality (%) 9.3  6.1 8.2  5.5
BMI (kg/m2) 24.8 (22.0/27.9) 24.9 (22.3/28.0)
Hypertension 72 (94) 52 (91)
Diabetes 18 (23) 14 (25)
Hypercholesterolemia 65 (84) 46 (81)
CAD 50 (65) 32 (56)
Peripheral artery disease 35 (46) 21 (37)
Previous MI 32 (42) 21 (38)
Previous PCI 37 (48) 25 (44)
Previous CABG 8 (10) 4 (7)
Previous stroke 20 (26) 16 (28)
Chronic renal failure 48 (62) 31 (54)
COPD 20 (26) 11 (19)
Pulmonary hypertension 32 (42) 20 (35)
Left ventricular EF (%) 45.3  16.8 46.4  15.8
Contrast medium (ml) 196  64 192  57
Time of procedure (min) 63  25 63  24
Central venous pressure (mm Hg) 8.4  5.0 8.0  4.5
Values are mean SD, n (%), or median with interquartile range (quartile 1 to quartile 3).
AKI  acute kidney injury; BMI  body mass index; CABG  coronary artery bypass grafting;EuroSCORE European System for Cardiac Operative Risk Evaluation; MImyocardial infarction; PCI peor Mann-Whitney U test, categorical variables with the
hi-square test. Pearson’s and Spearman’s correlation coef-
cients were used to establish associations. The cumulative
urvival plot in relation to creatinine according to quartiles
to 4 and the incidence of AKI was estimated by the
aplan-Meier method. Survival in groups was compared
ith the log-rank test. To identify predictors of death after
AVI, a Cox proportional hazard model was applied.
esults are reported as adjusted hazard ratio (HR) with
5% confidence interval (CI). All analyses were conducted
ith SPSS Statistics version 17.0.0 (SPSS, Inc., Chicago,
llinois).
esults
aseline characteristics. The TAVI was performed in 77
atients with severe, symptomatic aortic stenosis unsuitable
or open heart surgery due to multiple comorbidities.
aseline characteristics are given in Table 1. All patients
ere at high risk for conventional surgery as reflected by a
ean STS score of 9.3  6.1 and a mean logistic Euro-
CORE of 31.2 17.6%. Common comorbidities included
oronary artery disease (65%), chronic renal failure (62%),
eripheral artery disease (46%), pulmonary hypertension
42%), history of previous myocardial infarction (42%) or
troke (26%), and chronic obstructive pulmonary disease
COPD) (26%).
survivors (n  20) p Value No AKI (n  57) AKI (n  20) p Value
80.6  6.5 0.82 81.2  6.7 79.9  6.8 0.47
9 (45) 0.47 32 (56) 8 (40) 0.21
41.7  16.5 0.002 30.5  18.5 33.3  15.0 0.50
12.5  6.6 0.006 9.3  6.5 9.5  4.9 0.90
23.6 (19.5/27.4) 0.19 25.4 (22.5/28.1) 23.1 (21.7/27.1) 0.19
20 (100) 0.17 52 (91) 20 (100) 0.17
4 (20) 0.68 15 (26) 3 (15) 0.30
19 (95) 0.13 48 (84) 17 (85) 0.93
18 (90) 0.006 34 (60) 16 (80) 0.10
14 (70) 0.01 22 (39) 13 (65) 0.04
11 (55) 0.17 23 (41) 9 (45) 0.76
12 (60) 0.21 26 (46) 11 (55) 0.47
4 (20) 0.10 5 (9) 3 (15) 0.43
4 (20) 0.48 15 (26) 5 (25) 0.91
17 (85) 0.01 34 (60) 14 (70) 0.41
9 (45) 0.02 12 (21) 8 (40) 0.10
12 (60) 0.05 21 (36) 11 (55) 0.16
42.1  19.4 0.37 45.6  16.5 44.2  18.1 0.74
207  80 0.45 192  61 207  70 0.37
62  27.6 0.89 63  23 64  28 0.80
9.5  6.5 0.39 7.7  4.5 9.9  6.0 0.11
coronary artery disease; COPD  chronic obstructive pulmonary disease; EF  ejection fraction;e
Non
CAD rcutaneous coronary intervention; STS Society of Thoracic Surgeons.
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1144aseline characteristics and outcome. Procedural success
as achieved in 75 of 77 (97%) patients, with 1 periproce-
ural death (1%) due to cardiogenic shock after balloon
alvuloplasty and 1 conversion to open heart surgery (1%)
ue to valve embolization into the ascending aorta without
ossibility to implant a second valve. A second valve was
mplanted in 3 patients (4%) due to valve malposition with
evere peri-valvular prosthetic regurgitation. A total of 8
atients (10%) died within the first 30 days after TAVI.
n-hospital mortality rate was 14% (11 of 77 patients). The
-year mortality rate was 26% (20 of 77 patients). The
auses of death for these patients were: pneumonia/
epticemia (n  7), cardiorenal syndrome with multi-organ
ailure (n  7), congestive heart failure (n  4), cardiogenic
hock (n  1), fatal myocardial infarction (n  1), and
ntracerebral bleeding (n  1).
All Patients (n  77) Survivors (n  57)
AKI 20 (26) 8 (14)
eGFR
Increase 49 (64) 43 (75)
Decrease 25% 15 (19) 8 (14)
Dcrease 25%–50% 9 (12) 5 (9)
Decrease 50% 3 (4) 1 (2)
Peri-prosthetic regurgitation
None/trivial 36 (47) 31 (54)
Mild 29 (38) 20 (35)
Moderate 12 (15) 6 (11)
Severe 0 0
Central venous pressure (mm Hg) 9.4 4.5 9.2 4.8
Red blood cell transfusion, n (%) 36 (47) 27 (47)
SIRS, n (%) 24 (31) 14 (25)
Temperature 36.0°C or 38.0°C 6 (8) 3 (5)
Heart rate 90 beats/min 15 (19) 11 (19)
Respiratory rate 20/min 40 (52) 28 (49)
Leukocyte count 12 or 4 (109/l) 23 (30) 14 (25)
Values are n (%), n, or mean SD.
AKI acute kidney injury; eGFR estimated glomerular filtration rate; SIRS systemic inflamm
Table 3. Laboratory Parameters of Study Population at Baseline
All Patients (n  77) Survivors (n  57) Non
Serum creatinine (mg/dl) 1.25 (1.08/1.58) 1.21 (1.02/1.44) 1
eGFR (ml/min) 50.6 (38.2/63.8) 53.3 (44.9/64.6) 4
NT-proBNP (pg/ml) 3,657 (1,156/9,890) 2,783 (952/9,513) 6,8
Lactate (mmol/l) 1.3 (1.0/1.6) 1.3 (1.0/1.6)
Troponin I (g/l) 0.02 (0.02/0.09) 0.02 (0.02/0.07) 0
CRP (mg/l) 10.0 (3.3/20.0) 6.2 (2.9/19.0) 2
Hemoglobin level (g/dl) 12.2  1.6 12.3  1.7
Hematocrit (%) 37.2  4.5 37.4  4.6
Leukocyte count (109/l) 7.0  1.8 7.0  1.9
Platelet count (109/l) 208 (165/281) 207 (159/279) 2
Values are median with interquartile range (quartile 1 to quartile 3) or mean SD.CRP C-reactive protein; NT-proBNP N-terminal prohormone brain natriuretic peptide; other abbrevNonsurvivors had a higher logistic EuroSCORE (41.7 
6.5 vs. 27.6 16.7; p 0.002) and a higher STS mortality
core (12.5  6.6 vs. 8.2  5.5; p  0.006) and greater
requency of coronary artery disease (90% vs. 56%; p 
.006), peripheral arterial disease (70% vs. 37%; p  0.01),
hronic renal failure (85% vs. 54%; p  0.01), COPD (45%
s. 19%; p  0.02), and pulmonary hypertension (60% vs.
5%; p  0.05) (Table 1). On the second post-procedural
ay (48 h after TAVI), nonsurvivors suffered more fre-
uently from periprocedural AKI (60% vs. 14%; p 0.001),
elevant peri-prosthetic regurgitation (30% vs. 11%; p 
.03), and SIRS (50% vs. 25%; p  0.03) (Table 2).
enal function before and after TAVI. Serum creatinine
evels and eGFR at baseline significantly differed between
onsurvivors and survivors (1.50 [1.22 to 1.91] mg/dl vs.
.21 [1.02 to 1.44] mg/dl, p  0.01, and 41.2 [31.6 to
nsurvivors (n  20) p Value No AKI (n  57) AKI (n  20) p Value
12 (60) 0.001
0.006 0.001
6 (30) 49 (86) 0
7 (35) 6 (16) 9 (45)
4 (20) 1 (2) 8 (40)
2 (10) 0 3 (15)
0.03 0.02
5 (25) 31 (54) 5 (25)
9 (45) 21 (37) 8 (40)
6 (30) 5 (9) 7 (35)
0 0 0
9.8 3.7 0.60 9.2 4.6 9.7 4.4 0.70
9 (45) 0.83 26 (46) 10 (50) 0.82
10 (50) 0.03 12 (21) 12 (60) 0.002
3 (15) 0.18 3 (5) 3 (15) 0.21
4 (20) 0.99 8 (14) 7 (35) 0.07
12 (60) 0.48 26 (46) 14 (70) 0.15
9 (45) 0.10 11 (19) 12 (60) 0.002
sponse syndrome; TAVI transcatheter aortic valve implantation.
rs (n  20) p Value No AKI (n  57) AKI (n  20) p Value
2/1.91) 0.01 1.22 (1.08/1.49) 1.31 (1.07/1.87) 0.52
.6/55.6) 0.02 50.6 (42.6/62.7) 47.2 (36.1/66.5) 0.80
90/10,814) 0.03 3,649 (952/10,173) 4,042 (1,791/9,175) 0.57
/1.8) 0.53 1.3 (1.0/1.8) 1.2 (1.0/1.6) 0.62
0.02/0.13) 0.43 0.02 (0.02/0.08) 0.02 (0.02/0.11) 0.82
/35.4) 0.01 9.5 (3.4/20.0) 10.0 (2.8/31.7) 0.68
 1.6 0.48 12.4  1.6 11.8  1.7 0.19
 4.2 0.48 37.6  4.3 36.1  4.7 0.19
 1.7 0.57 7.2  1.8 6.7  1.9 0.31
0/283) 0.48 211 (182/287) 195 (148/277) 0.26Table 2. Clinical Characteristics of Study Population on Day 2 After TAVI
Nosurvivo
.50 (1.2
1.2 (31
61 (3,7
1.3 (1.2
.03 (
0.9 (5.3
12.0
36.6
7.1
17 (17iations as in Tables 1 and 2.
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11455.6] ml/min vs. 53.3 [44.9 to 64.6] ml/min, p  0.02,
espectively). Furthermore, NT-proBNP levels (6,861
3,790 to 10,814] pg/ml vs. 2,783 [952 to 9,513] pg/ml;
 0.03) and CRP levels (20.9 [5.3 to 35.4] mg/l vs. 6.2
2.9 to 19.0] mg/l; p  0.01) were significantly higher in
onsurvivors (Table 3).
Forty-eight hours after TAVI, a significant decrease of
erum creatinine and increase of eGFR in survivors com-
ared with nonsurvivors (1.02 [0.86 to 1.26] mg/dl vs. 1.55
1.25 to 2.58] mg/dl, p 0.001; 66.8 [50.7 to 79.3] ml/min
s. 37.2 [25.6 to 59.2] ml/min, p  0.001) was observed
Figure 1. Renal Function Before and After Transcatheter Aortic
Valve Implantation
Time course of serum creatinine (mg/dl) on days 0, 1, 2, 3, and 7 after
transcatheter aortic valve implantation according to outcome. In the box-
and-whisker plot, the central box represents the interquartile range (IQR);
the middle line represents the median. Outside values (●) are smaller/
larger than the lower/upper quartile  1.5 the IQR; far out values (*) are
smaller/larger than the lower/upper quartile  3 the IQR.
Table 4. Laboratory Parameters of Study Population on Day 2 After TAVI
All Patients (n  77) Survivors (n  57) No
Serum creatinine (mg/dl) 1.11 (0.90/1.43) 1.02 (0.86/1.26)
eGFR (ml/min) 60.2 (40.2/73.9) 66.8 (50.7/79.3)
NT-proBNP (pg/ml) 2,371 (820/5,759) 1,127 (730/5,139) 5
Lactate (mmol/l) 0.9 (0.7/1.1) 0.8 (0.6/1.0)
Troponin I (g/l) 0.77 (0.34/1.94) 0.51 (0.24/1.35)
CRP (mg/l) 74.5 (27.3/100.0) 63.6 (24.0/98.3)
Hemoglobin level (g/dl) 10.4  1.0 10.4  0.9
Hematocrit (%) 31.7  3.1 31.5  3.0
Leukocyte count (109/l) 11.4  4.6 10.9  4.4
Platelet count (109/l) 123 (97/170) 120 (92/170)
Values are median with interquartile range (quartile 1 to quartile 3) or mean SD.Abbreviations as in Tables 1, 2, and 3.Fig. 1, Table 4). Estimated GFR increased in 64% of all
atients; 19%, 12%, and 4% of patients had eGFR decreases
f 25%, 25% to 50%, and 50%, respectively (Table 2).
orrelation of baseline characteristics with renal function. Pre-
rocedural serum creatinine level and eGFR were associated
ith the logistic EuroSCORE (r  0.57, p  0.001; r 
0.31, p  0.009, respectively), the STS mortality score
r  0.55, p  0.001; r  0.42, p  0.001, respectively),
nd the pre-procedural NT-proBNP level (r  0.48, p 
.001; r  0.34, p  0.01, respectively). Furthermore,
ulmonary hypertension (p  0.03; p  0.04) was associ-
ted with serum creatinine level and eGFR at baseline,
espectively.
Figure 2. 1-Year Outcome According to Baseline Serum Creatinine
Survival rate according to quartiles (Qs) of baseline serum creatinine (mg/dl).
Q1: 1.08 mg/dl, Q2: 1.08 to 1.24 mg/dl, Q3: 1.25 to 1.57 mg/dl, Q4: 1.58
mg/dl.
vors (n  20) p Value No AKI (n  57) AKI (n  20) p Value
.25/2.58) 0.001 1.00 (0.84/1.24) 1.70 (1.35/2.64) 0.001
5.6/59.2) 0.001 66.8 (53.3/79.1) 38.0 (23.8/48.2) 0.001
,915/13,786) 0.002 1,128 (737/5,528) 3,959 (1,575/7,421) 0.03
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1146On the second post-procedural day, serum creatinine level
nd eGFR were associated with the leukocyte count (r 0.26,
 0.03; r0.37, p 0.002, respectively). No correlation
as observed between post-procedural serum creatinine and
GFR, and the amount of contrast medium (r  0.09, p 
.44; r  0.06, p  0.64, respectively).
enal function at baseline and outcome. Pre-procedural serum
reatinine levels were related to an increased 1-year mortality risk
cross quartiles: 10%, 16%, 26%, and 53%; p 0.008 (Fig. 2). A
re-procedural serum creatinine level 1.58 mg/dl (quartile 4
s. quartile 1 to 3) was associated with a 6-fold increased risk
f 30-day mortality (HR: 5.9, 95% CI: 1.4 to 24.8; p  0.02)
nd a 4-fold increased risk of 1-year mortality (HR: 3.9, 95%
I: 1.6 to 9.5; p  0.002) (Table 5).
KI after TAVI. Acute kidney injury according to the Acute
idney Injury Network classification (15) occurred in 20
atients (26%) after TAVI: 8 of 20 patients (40%) needed
emofiltration, and 12 of 20 patients (60%) with peripro-
edural AKI died during follow-up. The incidence of AKI
as related to peripheral arterial disease (65% vs. 39%; p 
.04); the occurrence of SIRS (60% vs. 21%, p  0.002);
nd post-procedural, peri-prosthetic regurgitation 2
35% vs. 9%; p  0.02) but independent of age, Euro-
CORE, STS mortality score, left ventricular ejection
raction, prevalence of COPD, aortic valve area, hematocrit,
latelet count, red blood cell transfusion, and the amount of
ontrast medium (Table 1). Acute kidney injury was not
elated to serum creatinine levels at baseline (p  0.52).
Patients with AKI showed—besides significantly in-
reased serum creatinine levels (1.70 [1.35 to 2.64] mg/dl vs.
.00 [0.84 to 1.24] mg/dl; p  0.001) and decreased eGFR
38.0 [23.8 to 48.2] ml/min vs. 66.8 [53.3 to 79.1] ml/min;
 0.001)—higher NT-proBNP (3,959 [1,575 to 7,421]
g/ml vs. 1,128 [737 to 5,528] pg/ml; p 0.03), lactate (1.1
0.8 to 2.2] mmol/l vs. 0.8 [0.6 to 1.0] mmol/l; p  0.001),
nd troponin I levels (1.20 [0.51 to 5.93] g/l vs. 0.53 [0.25
Table 5. Cox Regression Analysis of Association Bet
30-Da
HR (95% CI)
Logistic EuroSCORE 1.1 (1.0–1.1)
STS score: mortality 1.1 (1.0–1.2)
CAD 3.9 (0.5–31.9)
Pulmonary hypertension 4.6 (0.9–22.9)
COPD 1.7 (0.4–7.1)
Peripheral artery disease 3.7 (0.8–18.4)
Serum creatinine (Q4) 5.9 (1.4–24.8)
SIRS 2.9 (0.7–13.0)
Peri-prosthetic regurgitation 2 5.4 (1.0–26.7)
AKI 4.9 (1.2–20.4)
CI confidence interval; HR hazard ratio; Q4 fourth quartile; otheo 1.76] g/l; p  0.05) on day 2 after TAVI (Table 4). Inatients with AKI, CRP levels (90.5 [77.2 to 112.5] mg/l
s. 58.2 [20.4 to 93.0] mg/l; p 0.005) and leukocyte count
13.8  5.5 · 109/l vs. 10.4  3.8 · 109/l; p  0.004) were
ignificantly higher 48 h after TAVI.
KI and outcome. The occurrence of AKI after TAVI was
trongly associated with 30-day (p  0.02), 6-month (p 
.001), and 1-year mortality (p  0.001) (Fig. 3). The
elative decrease of eGFR was associated with outcome after
AVI: after 1 year, the mortality rate in patients with an
ncrease of eGFR was 12% versus 47%, 44%, and 67%,
Clinical Characteristics and Outcome
tality 1-Year Mortality
p Value HR (95% CI) p Value
0.02 1.0 (1.0–1.1) 0.002
0.02 1.1 (1.1–1.2) 0.001
0.20 4.6 (1.1–19.9) 0.04
0.06 3.1 (1.3–7.6) 0.01
0.47 2.9 (1.2–7.1) 0.02
0.11 2.3 (0.9–6.1) 0.08
0.02 3.9 (1.6–9.5) 0.002
0.16 2.5 (1.0–6.2) 0.04
0.05 4.2 (1.2–15.0) 0.03
0.03 5.9 (2.4–14.5) 0.001
viations as in Table 1.
Figure 3. 1-Year Outcome According to the Occurrence of
Periprocedural Acute Kidney Injury
Survival rate according to the occurrence of periprocedural acute kidney
injury (absolute increase in serum creatinine of 0.3 mg/dl [26.4 mol/l];
percentage increase in serum creatinine of 50%; or reduction in urine
output, deﬁned as 0.5 ml/kg/h for more than 6 h, in 48 h after TAVI,ween
y Moraccording to the Acute Kidney Injury Network classiﬁcation [15]).
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1147espectively, in patients with a decrease of eGFR of 25%,
5% to 50%, or 50%, respectively (p  0.006) (Table 2).
Patients suffering from AKI had a 5-fold increased risk
or 30-day mortality (HR: 4.9, 95% CI: 1.2 to 20.4, p 
.03) and a 6-fold increased risk for 1-year mortality (HR:
.9, 95% CI: 2.4 to 14.5, p  0.001) (Table 5).
iscussion
n our study, impaired renal function at baseline as reflected
y serum creatinine and the incidence of AKI were strong
redictors of short- and mid-term outcome after TAVI and
uperior to known clinical outcome parameters such as left
entricular ejection fraction, NT-proBNP level, and the
ogistic EuroSCORE.
The outcome of transfemoral TAVI patients in recently
ublished data with a 30-day mortality of 8% to 15% and a
-year mortality of 24% to 26% is comparable to our data
ith mortality rates of 10% and 26%, respectively, although
he logistic EuroSCORE (31.2  17.6%) in our patients
ended to be higher (7,9,10,22,23).
Chronic obstructive pulmonary disease, pulmonary hy-
ertension, and peripheral artery disease were predictors of
ortality after TAVI (7,9,17,19), consistent with other
ecently published studies about outcome after TAVI. As
ecently published from the German TAVI registry, a
oderate-to-severe peri-prosthetic regurgitation, which was
lso associated with the occurrence of AKI in our study,
ncreased mortality during follow-up (22).
enal function and mortality after TAVI. Renal function and
he development of AKI are important factors for the
utcome of patients after invasive procedures. Previously
ublished data underline the importance of AKI after TAVI
nd describe an incidence of 12% to 28%, which is compa-
able to our study (17–19). Webb et al. (9) recently showed
hat chronic kidney disease is associated with a significant
igher risk for cumulative late mortality. Bagur et al. (19)
ound that AKI after TAVI is associated with a more-than-
-fold increased post-procedural mortality risk, which is
onsistent with our data. Our study extends these findings,
ecause not only does the mortality risk increase stepwise
cross quartiles of baseline serum creatinine but also the
ccurrence of AKI is related to an increased mortality risk in
hort- and mid-term follow-up—independent of whether
enal function returns to baseline or not.
echanisms of AKI. An AKI after conventional cardiac
urgery or percutaneous coronary intervention is related to
rolonged hospital stay and mortality (12–15). An increase
f serum creatinine is not simply a marker of illness severity
ut rather represents the onset of AKI, which acts as a
ausative factor for cardiovascular injury with concomitant
ctivation of neurohormonal, immunological, and inflam-
atory pathways (24,25). Episodes of pre- and periproce-ural hypotension (i.e., rapid burst pacing during balloon nalvuloplasty, deployment of the valve prosthesis) might
ead to sublethal endothelial injury, which could impair the
roduction of vasodilatory substances such as endothelial
itric oxide and promote vasoconstriction resulting in tubu-
ar ischemia and injury (11,26).
Because the amount of contrast media was not associated
ith the occurrence of periprocedural AKI in our study, the
ephrotoxic mechanisms of contrast-induced nephropathy
hould not be the major issue. Nonetheless, the amount of
ontrast media needed during the procedure is higher for
he CoreValve prosthesis than for the Edwards-Sapien valve
17,19).
Because the incidence of AKI in our study was associated
ith the prevalence of peripheral arterial disease, advanced
eneralized atherosclerosis might play an additional role, as
reviously hypothesized by Aregger et al. (17). Bagur et al.
19) described red blood cell transfusion as an additional risk
actor for AKI after TAVI. However, this was not con-
rmed in our study.
Another factor that might influence renal function after
AVI could be moderate-to-severe peri-prosthetic regurgi-
ation with a prevalence of 7% to 19%, as published in
ecent data (6,7,22,27). A recent analysis of the German
AVI registry described an increased 30-day mortality risk
n patients with moderate-to-severe peri-prosthetic regur-
itation (22). In our study cohort, moderate peri-prosthetic
egurgitation was found in 15% of the patients and was
ssociated with the occurrence of AKI as well as increased
ortality: in multivariate analysis, patients had a 5-fold-
igher risk for 1-year mortality and/or AKI. Acute volume
verload with increased left ventricular end-diastolic pres-
ure due to relevant peri-prosthetic regurgitation might be
esponsible for hemodynamic changes with impairment of
iastolic renal blood flow and, thus, deterioration of renal
unction with consecutive kidney injury—especially in pa-
ients with low left ventricular ejection fraction.
The development of SIRS might contribute to the
ccurrence of AKI. Aregger et al. (17) observed a patho-
ogical leukocyte count and fever without focus in patients
ho developed AKI after TAVI. In our study, 60% of the
atients with AKI fulfilled the criteria of SIRS and showed
ignificantly higher leukocyte counts and CRP levels 48 h
fter TAVI. Animal models of renal ischemia-reperfusion
njury have demonstrated the pathologic role of interstitial
nflammation and the elaboration of cytokines and reactive
xygen species in the production of acute tubular necrosis
28,29).
Furthermore, particulate emboli generated during valvu-
oplasty, catheter passage in the aorta, and deployment of
he valve prosthesis not only might play a role for cerebral
utcome after TAVI (30,31) but also might be in part
esponsible for the postoperative decrease in eGFR (32).
Thus, hemodynamic, inflammatory, atheroembolic, and
ephrotoxic factors are involved and overlap each other in
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1148eading to an abrupt worsening of renal function, which
ight lead to the so-called cardiorenal syndrome with acute
ardiac dysfunction (25,33,34). In our study, patients with
KI had higher NT-proBNP levels on day 2 compared
ith patients without AKI. The 30-day mortality was 44%
4 of 9) in patients with a combination of AKI and an
T-proBNP increase, compared with 6% (4 of 68) in all
ther TAVI patients (HR: 8.3, 95% CI: 2.1 to 33.6; p 
.003). In these patients, the coincidence of acute renal and
ardiac failure might have led to the development of a
ardiorenal syndrome with very poor prognosis. Data from
ardiac surgery studies point to a concerted injury with the
nvolvement of multiple factors, which results in acute
ubular necrosis (11,29). Excessive activation of the renin-
ngiotensin-aldosterone axis, renal dysfunction with sodium
nd water retention, and acute myocardial ischemia from an
ncrease in myocardial oxygen demand related to sympa-
hetic activation and peripheral vasoconstriction are the
uggested pathways after cardiac surgery and presumably
fter TAVI, leading to a vicious circle with severe kidney
amage followed by a systemic injury leading to the death of
he patient (25).
Because the occurrence of periprocedural AKI is multi-
actorial and related to several (post-procedural) clinical
haracteristics (moderate-to-severe peri-prosthetic regurgi-
ation, SIRS, and the like), every effort has to be made in
AVI patients to avoid or treat these complications. Espe-
ially in patients with multiple comorbidities and a high-
railty index (7,35), preprocedural renal function should be
major issue in the selection process for TAVI and could be
reason for exclusion, because it plays a pivotal role for
utcome. The prevention and/or treatment of AKI should
ead to a better long-term outcome after TAVI; but several
ssues, like the coincidence with relevant peri-prosthetic
egurgitation and SIRS, are not yet fully understood.
hether a moderate-to-severe peri-prosthetic regurgitation
redisposes for the development of AKI and acute cardio-
enal syndrome or whether the development of SIRS
ontributes to adverse outcome of TAVI patients remains
ontroversial and has to be elucidated in further studies
bout the pathophysiology of AKI after TAVI.
A larger controlled multicenter trial is needed to further
alidate our data, because it would have major implications
n the selection process as well as preventive treatment of
AVI patients. For the time being, strategies to prevent
KI in TAVI patients remain an important challenge.
reventive strategies in TAVI patients at risk for AKI
nclude pre- and periprocedural hydration, the potential use
f N-acetylcysteine, and intravenous bicarbonate applica-
ion. However, no specific pharmacological intervention has
emonstrated conclusive efficacy in the prevention of AKI
11). To prevent nephrotoxic mechanisms, iso-osmolar
ontrast agents should be used, and their amount has to be
ept low. After development of the valve prosthesis, addi-ional balloon valvuloplasty or valve-in-valve implantation
hould be considered in patients with moderate-to-severe
eri-prosthetic regurgitation to downgrade a relevant regur-
itation and avoid negative hemodynamic effects on the
atient, especially in case of markedly impaired left ventric-
lar function. Data about prophylactic hemofiltration in
atients with AKI after cardiac surgery are empirical (36),
ut hemofiltration might improve outcome of patients
eveloping an acute cardiorenal syndrome after TAVI.
tudy limitations. Sample size and the monocentric charac-
er are limitations of our prospective observational study.
urthermore, only univariate regression analysis has been
resented, because the event count was not sufficient to
upport multivariate analysis with inclusion of all 10 mor-
ality predictors in our study, and thus a multivariate model
ould have been overfitted. However, AKI was an indepen-
ent predictor for 30-day and 1-year mortality when mul-
ivariate analysis was performed. With the increasing use of
AVI in high-risk patients, identification of clinical criteria
s important to optimize patient selection and post-
rocedural management. Hypothesis-generating studies are
f pivotal interest to design larger randomized studies. The
ype of AKI (ischemic, nephrotoxic, or atheroembolic)
ould not be determined in our study, because renal biopsies
ere not performed. Because of the nature of the patients
nd the performed procedures, AKI was assumed to be
ultifactorial. Thus, our data cannot establish whether the
evelopment of AKI is a marker of multisystem failure in
ritically ill patients or directly contributes to mortality or
oth.
onclusions
mpaired renal function at baseline and the occurrence of
eriprocedural AKI—independent whether renal function
eturns to baseline or not—are strong predictors of 30-day
nd 1-year mortality after TAVI. The development of AKI
as related to peripheral artery disease, moderate-to-severe
eri-prosthetic regurgitation, and the development of SIRS.
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